FDA expands Bravecto Quantum tick label for dogs
Bottom line
Merck Animal Health said the FDA has approved an expanded label for Bravecto Quantum, its long-acting fluralaner injection for dogs, adding 12-month treatment and control claims for the Asian longhorned tick (Haemaphysalis longicornis) and Gulf Coast tick (Amblyomma maculatum). The product was originally approved on July 10, 2025, as the first FDA-approved flea and tick drug for dogs with 8- to 12-month protection, depending on tick species. With this March 18, 2026 label expansion, Bravecto Quantum now carries 12-month claims for five tick species, while lone star tick coverage remains at 8 months. It remains indicated for dogs and puppies 6 months of age and older, and it must be prescribed and administered by a licensed veterinarian. (merck-animal-health-usa.com)
Why it matters: For veterinary professionals, the update broadens the label at a time when parasite risk is shifting geographically. USDA says the invasive Asian longhorned tick can establish large infestations and spread quickly because females can reproduce without mating, while the Gulf Coast tick is a recognized veterinary concern in dogs. The expanded label may make Bravecto Quantum more attractive in clinics looking for longer-duration compliance support, but veterinarians still need to match dosing intervals to local tick pressure because potential lone star tick exposure still requires redosing at 8 months. That distinction has also drawn outside scrutiny: in March 2026, BBB National Programs’ National Advertising Division said Merck should modify or discontinue some unqualified “once-a-year” tick-protection claims, though it found the company had support for a general safety claim. (aphis.usda.gov)
What to watch: Watch for how quickly practices adopt the expanded indication in endemic and emerging tick markets, and whether Merck changes marketing language as its appeal of the NAD decision moves forward. (bbbprograms.org)
Merck Animal Health has won an FDA label expansion for Bravecto Quantum, adding 12-month treatment and control claims in dogs for the Asian longhorned tick and Gulf Coast tick. The March 18, 2026 update extends the product’s reach against two species that matter to veterinarians tracking shifting parasite geography, while keeping Bravecto Quantum positioned as a veterinarian-administered, long-duration option in canine ectoparasite prevention. (merck-animal-health-usa.com)
That expansion builds on Bravecto Quantum’s original FDA approval on July 10, 2025. At launch, the injectable fluralaner suspension became the first FDA-approved flea and tick drug for dogs to provide 8 to 12 months of protection, depending on tick species. The original label covered fleas for 12 months, plus black-legged tick, American dog tick, and brown dog tick for 12 months, with lone star tick coverage limited to 8 months. FDA also stressed that the product must be prescribed by a licensed veterinarian, both because it is injected in-clinic and because veterinarians need to determine whether the appropriate retreatment interval is 8 or 12 months based on likely tick exposure. (fda.gov)
Under the expanded label, Bravecto Quantum now carries 12-month claims for Asian longhorned tick, Gulf Coast tick, black-legged tick, American dog tick, and brown dog tick after a single veterinarian-administered injection. The product remains indicated to kill adult fleas and prevent flea infestations in dogs and puppies 6 months of age and older. Merck framed the update as a response to an evolving parasite landscape, particularly as Asian longhorned and Gulf Coast ticks continue to spread or gain clinical relevance in more areas. (merck-animal-health-usa.com)
The background on Asian longhorned tick helps explain why this label change stands out. USDA APHIS describes the species as an invasive tick that can create heavy infestations, and notes that U.S. populations can reproduce without mating, a trait that supports rapid establishment and spread. USDA and ARS materials also note the tick has been found on domestic animals, including dogs, in the United States. Gulf Coast tick brings a different concern set: it has long been recognized in veterinary literature as the likely vector of Hepatozoon americanum, the agent associated with American canine hepatozoonosis. Taken together, those species-specific risks make broader labeled coverage more relevant than a routine line extension. (aphis.usda.gov)
Merck’s announcement was promotional, but there is also a note of caution in the surrounding market conversation. Earlier this month, BBB National Programs’ National Advertising Division said Merck had support for the claim that Bravecto Quantum is “a safe, effective way to protect dogs year round,” but recommended that the company modify or discontinue certain claims implying that one injection universally provides a full year of tick protection. The reason is the same one FDA highlighted at approval: dogs with potential exposure to lone star ticks still need an 8-month dosing interval. Merck said it would appeal portions of that decision. (bbbprograms.org)
Why it matters: For veterinary teams, the practical value here is twofold. First, the label expansion gives clinics a stronger on-label option for pet parents seeking lower-friction parasite prevention, especially where adherence to monthly or every-12-week products is inconsistent. Second, it sharpens the need for region-specific parasite risk assessment. “Once yearly” is accurate for some tick exposures, but not all. Practices will still need clear protocols for counseling pet parents about local species prevalence, travel history, and when an 8-month revisit is needed because of lone star tick risk. FDA’s own safety communication also remains relevant: isoxazolines are widely used, but the class has been associated with neurologic adverse reactions in some dogs and cats. (fda.gov)
There’s also a competitive angle. Companion animal parasiticide makers have been racing to add label claims tied to emerging or expanding tick threats, including Asian longhorned tick. In that context, Bravecto Quantum’s expanded label strengthens Merck’s differentiation around long duration and in-clinic administration, particularly for practices that see compliance as a medical and business issue, not just a convenience issue. That said, the injectable format means uptake will still depend on case selection, client education, and confidence in aligning the dosing interval with real-world exposure. (elanco.com)
What to watch: The next signals will be whether veterinary practices in emerging tick regions begin using the expanded claims more actively in prevention protocols, and whether Merck’s marketing language changes as the NARB appeal process plays out. (bbbprograms.org)